Trial Profile
An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab; Sunitinib; Vinflunine
- Indications Bladder cancer; Non-small cell lung cancer; Renal cancer; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- Acronyms IMbrella A
- Sponsors Chugai Pharmaceutical; Roche
- 17 Feb 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
- 13 Jan 2024 This trial has been completed in Czech Republic.
- 15 Nov 2023 Number of treatment arms increased from 1 to 3 by the addition of an experimental arm (Combined Agents with Atezolizumab) and an active comparator (Bevacizumab) arm. Study design is changed from single-group assignment to parallel.